• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: DURECT Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    11/29/24 2:30:08 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    8-K/A
    true000108203800010820382024-11-222024-11-22

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K/A

     

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    November 22, 2024

    Date of Report

    (Date of earliest event reported)

     

    DURECT CORPORATION

    (Exact name of Registrant as specified in its charter)

     

    Delaware

     

    000-31615

     

    94-3297098

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    10240 Bubb Road

    Cupertino, CA 95014

    (Address of principal executive offices) (Zip code)

    (408) 777-1417

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

    Trading Symbol

    Name of Each Exchange on Which Registered

    Common Stock $0.0001 par value per share

    Preferred Share Purchase Rights

     

    DRRX

    The NASDAQ Stock Market LLC

    (The Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

     

     


     

    EXPLANATORY NOTE

    On November 25, 2024, DURECT Corporation (the “Company”) filed with the Securities and Exchange Commission a Current Report on Form 8-K (the “Initial 8-K”) to disclose that it had completed its sale of ALZET Product Line to Lafayette Instruments Co. (the “Transaction”). This Form 8-K/A amends the Initial 8-K to include the pro forma financial information of the Company giving effect to the completion of the Transaction required by Item 9.01(b) of Form 8-K.

    Item 9.01 Financial Statements and Exhibits

    (b) Pro Forma Financial Information.

    The following unaudited pro forma condensed financial information of the Company, giving effect to the Transaction, is attached hereto as Exhibit 99.1 and is incorporated herein by reference:

    •
    Unaudited Pro Forma Condensed Balance Sheet as of September 30, 2024;
    •
    Unaudited Pro Forma Condensed Statement of Operations and Comprehensive Loss for the Nine Months Ended September 30, 2024; and
    •
    Unaudited Pro Forma Condensed Statement of Operations and Comprehensive Loss for the Year Ended December 31, 2023.

     

    (d) Exhibits

     

    99.1

    Unaudited Pro Forma Condensed Financial Information of the Company

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    2


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    DURECT Corporation

     

     

     

     

     

    Date: November 29, 2024

     

    By:

     

    /s/ James E. Brown

     

     

     

     

        James E. Brown

        President and Chief Executive Officer

     

     

     

     

     

     

    3


    Get the next $DRRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Durect with a new price target

      HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

      5/5/21 6:31:29 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Durect with a new price target

      Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      2/3/21 8:15:53 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

      5/13/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care